Open AccessDurable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis
Author(s) -
Ide Maako,
Tanaka Kentaro,
Sunami Shunya,
Asoh Tatsuma,
Maeyama Takashige,
Tsuruta Nobuko,
Nakanishi Yoichi,
Okamoto Isamu
Publication year - 2018
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.12853
Subject(s) - medicine , nivolumab , idiopathic pulmonary fibrosis , lung cancer , pulmonary function testing , adenocarcinoma , lung , usual interstitial pneumonia , exacerbation , oncology , gastroenterology , cancer , immunotherapy
The efficacy and safety of immune‐checkpoint inhibitors in non‐small cell lung cancer patients with idiopathic pulmonary fibrosis (IPF) remain unknown. Herein, we describe the case of a 62‐year‐old man with multiple pleural tumors and carcinomatous pleurisy. High‐resolution computed tomography indicated usual interstitial pneumonia, and a respiratory function test revealed a restrictive disorder and decreased diffusion capacity. He was diagnosed with lung adenocarcinoma and IPF. After failure of initial chemotherapy, he was treated with nivolumab and achieved a complete response without any sign of exacerbation of IPF. The response to nivolumab has persisted for > 1 year. This is the first report of a non‐small cell lung cancer patient with IPF who has been treated with immune‐checkpoint inhibitors for such a long period and achieved a sustained response.